FluorThanatrace

Phase 1Small molecule

WWashington University School of Medicine

FluorThanatrace is one of 183 small molecule programs targeting Paraganglioma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

182

Competitors

Pipeline

Status by Indication[3][1]

Indication

ParagangliomaActive, not recruiting

Pancreatic Neuroendocrine TumorActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

Breast CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

ParagangliomaPhase 1

Active, not recruiting

Pancreatic Neuroendocrine TumorPhase 1

Active, not recruiting

Metastatic Prostate CancerPreclinical

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Pancreatic CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 3

MS Contin

Merck & Co.

Preclinical

2 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

FluorThanatrace

WWashington University School of Medicine

Phase 1

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Zinecard

CChildren's Oncology Group

Preclinical

2 8

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 9

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 10

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Paraganglioma

NCT05636540

Q3 2027

Phase 1Active, not recruiting

Breast Cancer

NCT03083288

Recruiting

Prostate Cancer Metastatic

NCT05242744

Phase 1Recruiting

Pancreatic Neuroendocrine Tumor

NCT07114939

Clinical

Trials by Indication[1]

Imaging1 trial

PET Imaging of PARP Activity in Cancer

Unknown status·WWashington University School of Medicine·Phase 1·NCT02469129·50 enrolled

Pilot Study1 trial

Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Recruiting·—·Phase 1·NCT02637934·35 enrolled

Pancreatic Neuroendocrine Tumor1 trial

FTT PET/CT in Pancreatic Neuroendocrine Tumors

Recruiting·—·Phase 1·NCT07114939·12 enrolled

Pancreatic Cancer1 trial

In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer

Terminated·—·Phase 1·NCT03492164·6 enrolled

Paraganglioma1 trial

In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma

Recruiting·HHeather Wachtel·Phase 1·NCT05636540·30 enrolled

2 more indications

Breast Cancer1 trial

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer

Active, not recruiting·AAbramson Cancer Center at Penn Medicine·Phase 1·NCT03083288·30 enrolled

Prostate Cancer Metastatic1 trial

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Patients With Metastatic Prostate Cancer

Recruiting·AAbramson Cancer Center at Penn Medicine··NCT05242744·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for FluorThanatrace. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FluorThanatrace compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FluorThanatrace. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: WWashington University School of Medicine

FluorThanatrace

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Trials by Indication[1]

Imaging1 trial

Pilot Study1 trial

Pancreatic Neuroendocrine Tumor1 trial

Pancreatic Cancer1 trial

Paraganglioma1 trial

Breast Cancer1 trial

Prostate Cancer Metastatic1 trial

References

Drug Info

Quick Facts

Related News